Predictive value of biomarkers for the prognosis of acute pulmonary embolism in Japanese patients: Results of the Tokyo CCU Network registry  by Tanabe, Yasuhiro et al.
Journal of Cardiology 66 (2015) 460–465Original article
Predictive value of biomarkers for the prognosis of acute pulmonary
embolism in Japanese patients: Results of the Tokyo CCU Network
registry
Yasuhiro Tanabe (MD)*, Toru Obayashi (MD, PhD), Takeshi Yamamoto (MD, PhD),
Morimasa Takayama (MD, PhD), Ken Nagao (MD, PhD)
Tokyo CCU Network Scientiﬁc Committee, Tokyo, Japan
A R T I C L E I N F O
Article history:
Received 17 November 2014
Received in revised form 9 February 2015
Accepted 25 February 2015







A B S T R A C T
Background: Several studies from Western countries have reported associations between cardiac
troponin and B-type natriuretic peptide (BNP) levels and acute pulmonary embolism prognosis;
however, the number of such reports from Asian countries, including Japan, is limited. Thus, we
evaluated the relationship between blood biochemical ﬁndings and acute-phase pulmonary embolism
prognosis in Japanese patients.
Methods: The subjects included 441 patients with acute pulmonary embolism (191 men, 250 women;
average age, 65.8  16.0 years) treated at Tokyo CCU Network Institutions from 2009 to 2011 and registered
via survey forms. The association between blood biochemical ﬁndings at admission and 30-day mortality was
investigated.
Results: The median BNP value was 186.5 pg/mL (25th to 75th interquartile range: 49.8–500 pg/mL) of
210 cases. No deaths were recorded among those with BNP levels <90 pg/mL (n = 70), whereas
signiﬁcantly higher mortality (10 deaths/140 cases, 7.1%; p = 0.033) was observed among those with BNP
levels 90 pg/mL. A qualitative cardiac troponin test was positive in 58 of the 204 cases (28.4%), with a
signiﬁcantly higher mortality incidence (p = 0.017) among the troponin-positive cases [6 (10.3%) versus
3 (2.1%) deaths among the 146 troponin-negative cases]. The overall mean blood glucose level at
admission of 331 cases was 152.0  74.0 mg/dL, and 30-day mortality signiﬁcantly increased with blood
glucose values (p = 0.048).
Conclusions: Troponin, BNP, and blood glucose levels are useful prognostic biomarkers for acute
pulmonary embolism in Japanese patients.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Acute pulmonary embolism is a critical disease; the reported
high acute phase mortality ranges from 7.9 to 14% [1–4]. The
prognosis is particularly poor for massive-type and collapse-type
pulmonary embolisms that present with shock and circulatory
collapse. In an aggregate survey by the Tokyo CCU Network,
hospital mortality was found to increase according to severity,
with all-cause mortality rates of 4% for non-massive, 7% for sub-
massive, 23% for massive, and 70% for collapse types [4,5]. Previous* Corresponding author at: Division of Cardiology, Department of Internal
Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku,
Kawasaki-City, Kanagawa 216-8511, Japan. Tel.: +81 44 977 8111;
fax: +81 44 976 7093.
E-mail address: y-tanabe@muj.biglobe.ne.jp (Y. Tanabe).
http://dx.doi.org/10.1016/j.jjcc.2015.03.002
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsstudies show that mortality is high for both massive- and collapse-
type pulmonary embolisms that present with circulatory failure;
however, non-massive and sub-massive types in which the
circulatory dynamics are stable at onset also have comparatively
high mortality rates. Therefore, factors other than hemodynamics
that could predict which cases require multidisciplinary treatment
due to poor prognosis are desired.
The utility of blood biomarkers such as cardiac troponin, B-type
natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide
(NT-Pro-BNP), and blood glucose levels has been reported to be
predictors of adverse events and poor prognosis in patients with
pulmonary embolism from Western countries; however, reports
from Asia, including Japan, are scarce, suggesting that such
biomarkers are underexploited in daily clinical practice.
The Tokyo CCU Network cardiac emergency transport system
was established in 1978 and is jointly run by the Tokyo Metropolitan reserved.
601 consecutive cases treated in the 
Tokyo CCU Network and registered 
between 2009 and  20 11.
160 cases were excluded  because 




BNP, 135  cases




BNP, 53  cases
Troponin,  61  cases
Glucose, 91  cases
Massive
(N = 35)
BNP, 15  cases
Troponin,  20  cases




Troponin,  7 cases
Glucose,15 cases
Fig. 1. Study population. Between 2009 and 2011, 601 consecutive patients with
acute pulmonary embolism were treated at institutions of the Tokyo CCU Network
and registered by survey-forms. Of these, 160 cases were excluded because of
insufﬁcient information. Therefore, 441 cases were enrolled in this study. BNP, B-
type natriuretic peptide.
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CCUs of each hospital and works to improve the emergency
treatment and transport of emergent cardiac disease patients in
Tokyo. Registry enrollment is recommended for all patients treated
at CCUs, and the obtained data are analyzed by the Tokyo CCU
Network Scientiﬁc Committee [4,5].
The aims of the present study were to elucidate the relation-
ships between blood biochemistry markers and the prognosis of
acute-phase pulmonary embolism in patients treated at the CCUs
of 67 Tokyo CCU Network participating institutions.
Materials and methods
Between 2009 and 2011, 601 consecutive patients with acute
pulmonary embolism were treated at Tokyo CCU Network
institutions and registered by survey forms; 160 cases were
excluded from the present analysis because of insufﬁcient
description. Therefore, 441 cases were enrolled in this study;
BNP, cardiac troponin, blood glucose, and D-dimer were evaluated
in 210, 204, 331, and 389 cases, respectively, at admission (Fig. 1).
Pulmonary embolism severity was categorized by physicians at
each institution based on blood pressure, echocardiography, and
computed tomography (CT) ﬁndings as either the non-massive
type (not accompanied by right heart strain, N = 279), sub-massive
type (right heart strain is present but circulatory dynamics are
stable, N = 109), massive type (right heart strain is present with
shock vital signs, or resting systolic blood pressure is reduced by
>40 mmHg, N = 35), or collapse type (circulation has collapsed,
N = 18). The study population is shown in Fig. 1. Treatment
decisions, such as thrombolysis, catheter treatment, and surgical
embolectomy, were made entirely by the attending physicians.
Anticoagulant treatment alone was performed in 244 cases
(55.3%), systemic thrombolysis in 139 (31.5%), catheter treatment
in 36 (8.2%), and surgical embolectomy in 4 (0.9%); other or
unknown treatments were used in 18 cases (4.1%). The relation-
ships among the acute-phase prognosis, blood test ﬁndings, and
pulmonary embolism severity at admission were evaluated. The
methods adopted for the cardiac troponin test varied among the
institutions and included either a qualitative immunochromato-
graphic cardiac troponin T test or a quantitative enzyme-linked
immunosorbent assay-based cardiac troponin T and I test.
Consequently, qualitative troponin T-positive or quantitative
troponin T and I tests that detected levels >0.1 ng/mL were
considered as positive in this study. For D-dimer, because
measurement kits differed among the institutions, values above
the reference value used by each institution were deﬁned as
D-dimer positive.
PASW Statistics ver. 18 (SPSS Inc., Chicago, IL, USA) was used to
compare means between two groups with the Student’s t-test;
comparisons of more than three groups were performed with theTable 1
Patients characteristics.
Non-massive (N = 279) Sub-massive (N = 10
Age (years) 65  16 67  16 
Sex (M/F) 129/150 45/64 
SBP (mmHg) 133  25 126  25 
DBP (mmHg) 80  16 79  19 
HR (min1) 88  20 97  21 
SatO2 (%) 93.3  5.8 90.2  8.6 
D-dimer positive 93.6% 98.8% 
BNP (pg/mL) (N = 210) 133.1 (N = 135) 321.4 (N = 53) 
Troponin positive
(N = 204)
30.2% (35 of 116 cases) 18.0% (11 of 61 case
Blood glucose (mg/dL)
(N = 331)
142  69 (N = 202) 145  58 (N = 91) 1-way analysis of variance. For non-parametrically distributed
data, Mann–Whitney U-tests and Kruskal–Wallis tests were used.
Incidence rates of phenomena were compared with the chi-
squared test. Statistical signiﬁcance was set at p < 0.05.
Results
Patient backgrounds and 30-day mortality according to severity
Patients’ backgrounds are shown in Table 1. Of the total
441 patients, 191 were men (43.3%), and 250 were women
(56.7%), with a mean age of 65.8  16.0 years. Pulmonary
embolism severity was classiﬁed as non-massive, sub-massive,
massive, and collapse types in 279 (63.3%), 109 (24.7%), 35 (7.9%),
and 18 (4.1%) cases, respectively. Blood pressure, heart rate, SatO2,
BNP levels, and blood glucose levels were signiﬁcantly different
among the groups.
Among all patients, 27 died within 30 days (6.1%) and
414 survived (93.9%). All-cause 30-day mortality was 1.8%
(5/279), 5.5% (6/109), 22.9% (8/35), and 44.4% (8/18) for the
non-massive, sub-massive, massive, and collapse types, respec-
tively, demonstrating an increase in 30-day mortality with
increasing pulmonary embolism severity (p < 0.001; Fig. 2). Cause
of death was circulatory failure in eight cases, recurrence of
pulmonary embolism in six cases, multiple organ failure in ﬁve
cases, cancer in three cases, gastrointestinal bleeding in one case,
pneumonia in one case, and ‘‘other’’ in three cases.9) Massive (N = 35) Collapse (N = 18) p value
66  15 71  16 0.34
10/25 7/11 0.22
108  25 88  19 <0.001
68  17 58  12 <0.001
106  18 102  37 <0.001
88.6  10.2 91.7  9.8 0.003
100% 91.7% 0.11
350.0 (N = 15) 231.0 (N = 7) 0.003
s) 50.0% (10 of 20 cases) 28.6% (2 of 7 cases) 0.046
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Fig. 2. Thirty-day mortality according to severity. The 30-day mortality rates
according to severity were 1.8% (5/279) among non-massive type cases, 5.5%
(6/109) among sub-massive type cases, 22.9% (8/35) among massive-type cases,
and 44.4% (8/18) among collapse-type cases. Increases in the 30-day mortality were
directly proportional to increases in pulmonary embolism severity (p < 0.001).
Fig. 4. Receiver operating characteristic curve analysis for assessing the capacity of
BNP to predict 30-day mortality provided an AUC of 0.73 (p = 0.016; 95% conﬁdence
interval, 0.589–0.862). AUC, area under the curve. BNP, B-type natriuretic peptide.
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BNP levels were measured in 261 cases, ranging from 3.6 to
2460 pg/mL with a median value of 186.5 pg/mL (25th to 75th
interquartile range: 49.8–500 pg/mL). Median BNP values were
133.1 pg/mL (25th to 75th interquartile range: 37.1–378.0 pg/mL)
for the non-massive type (n = 135); 321.4 (25th to 75th
interquartile range: 107.9–585.2) for the sub-massive type
(n = 53); 350.0 (25th to 75th interquartile range: 114.0–708.0)
for the massive type (n = 15); and 231.0 (25th to 75th interquartile
range: 105.0–625.6) for the collapse type (n = 7). A signiﬁcant
difference was observed among the severity levels (p = 0.003;
Table 1). The median BNP level for the 30-day mortality group
(data available for 10 cases) was 545.0 pg/mL (25th to 75th
interquartile range: 169.8–761.2 pg/mL), signiﬁcantly higher
than the median 181.6 pg/mL (25th to 75th interquartile range:
45.2–464.0 pg/mL) among survivors (n = 200; p = 0.016; Fig. 3).
Receiver operating characteristic (ROC) curve analysis for asses-
sing the capacity of BNP to predict 30-day mortality provided an
area under the curve (AUC) value of 0.73 (p = 0.016; 95% conﬁdence
interval, 0.589–0.862, Fig. 4). Using a cut-off value of 90 pg/mL,Fig. 3. BNP levels and 30-day mortality. Regarding all-cause, 30-day mortality, the
median BNP level of the 30-day mortality group (n = 10) was 545.0 pg/mL (25th to
75th interquartile range: 169.8–761.2 pg/mL), which was signiﬁcantly higher than the
median level of 181.6 pg/mL (25th to 75th interquartile range: 45.2–464.0 pg/mL) in
the surviving group (n = 200; p = 0.016). BNP, B-type natriuretic peptide.there were 0 deaths (0%) among the 70 cases with BNP levels
<90 pg/mL, whereas there were 10 deaths (7.1%) among the
140 cases with BNP levels 90 pg/mL (p = 0.033); the correspond-
ing sensitivity, speciﬁcity, positive predictive value, and negative
predictive values were 100%, 35.0%, 7.1%, and 100%, respectively.
Cardiac troponin
Cardiac troponin tests were performed in 204 cases, and 58
(28.4%) were positive. The positivity rates were 30.2%, 18.0%, 50%,
and 28.6% for the non-massive, sub-massive, massive, and collapse
types, respectively (Table 1).
All-cause 30-day mortality among the troponin-positive and -
negative cases is shown in Fig. 5. The 30-day mortality rate for
troponin-positive cases was 10.3%, signiﬁcantly higher than the
2.1% for -negative cases (p = 0.017). The troponin positivity test
had a sensitivity, speciﬁcity, positive predictive value, and negative
predictive value of 66.7%, 73.3%, 10.3%, and 97.9%, respectively, for
30-day mortality.
The relationship between the troponin-positive rate and the
time from onset to blood test was evaluated in 127 cases. In(%) P = 0.017












Fig. 5. Troponin status and 30-day mortality. The 30-day mortality rate for
troponin-positive cases was 10.3%; this value was signiﬁcantly higher than the rate
of 2.1% for negative cases (p = 0.017). Additionally, regarding 30-day mortality, the
troponin positivity test had a sensitivity, speciﬁcity, positive predictive value, and
negative predictive value of 66.7%, 73.3%, 10.3%, and 97.9%, respectively.
Fig. 7. Receiver operating characteristic curve analysis for assessing the capacity of
blood glucose to predict 30-day mortality provided an AUC of 0.67 (p = 0.013; 95%
conﬁdence interval, 0.560–0.781). AUC, area under the curve.
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results were all negative regardless of acute pulmonary embolism
severity.
Blood glucose
The mean recorded blood glucose levels at admission (available
for 331 patients) was 152.0  74.0 mg/dL (range, 76–632 mg/dL).
Blood glucose levels increased signiﬁcantly with pulmonary embo-
lism severity (p < 0.001; Table 1). Among the 224 patients with blood
glucose levels at admission between 70 and <150 mg/dL, 8 (3.6%)
died within 30 days, signiﬁcantly fewer than the 11 (10.3%) who died
among the 107 patients with glucose levels 150 mg/dL (p = 0.021;
Fig. 6). Consequently, 30-day mortality signiﬁcantly increased with
blood glucose values (p = 0.048), and the ROC curve analysis for
assessing blood glucose’s ability to predict 30-day mortality provided
an AUC of 0.67 (p = 0.013; 95% conﬁdence interval, 0.560–0.781,
Fig. 7).
D-Dimer
The D-dimer test was performed in 389 patients and 372 were
positive, resulting in an extremely high incidence (95.6%). A high
incidence of D-dimer positivity was observed at each pulmonary
embolism severity level, with rates of 93.6% (175/187), 98.8%
(82/83), 100% (20/20), and 91.7% (11/12) for the non-massive, sub-
massive, massive, and collapse types, respectively; these differ-
ences were not signiﬁcant (Table 1). Additionally, no difference in
30-day mortality was observed according to D-dimer status.
Discussion
In Japan, the incidence of acute pulmonary embolism increased
by 2.25-fold during the past decade, along with the westernization
of lifestyles [1,2], progress in the diagnostic methods [such as
computed tomography (CT) and magnetic resonance imaging]
[6,7], and the improved perception of this disease. However,
differences in morbidity according to race remain considerable,
and the rate of 62 per 1,000,000 people annually in Japan is one-
ninth of the Western rate of 500–600 per 1,000,000 people
annually [1–3]. Therefore, it is difﬁcult to obtain evidence
regarding acute pulmonary embolism in Japan due to the small
number of cases.Fig. 6. Blood glucose levels at admission and 30-day mortality. Among the
224 patients with blood glucose levels at admission between 70 and <150 mg/dL, 8
(3.6%) died within 30 days, which was signiﬁcantly lower than that of 11 (10.3%)
among the 107 patients with glucose levels 150 mg/dL (p = 0.021).When diagnosing acute pulmonary embolism, it is important to
perform a rapid diagnosis and precise risk stratiﬁcation followed
by selecting a treatment appropriate to the risk level [2,3]. First,
cases with unstable circulatory dynamics have a high risk;
however, even cases with stable circulatory dynamics have
hospital mortality rates of 4–7% [2–5], so it is necessary to
separate cases with an intermediate risk from those with stable
hemodynamics. In the West, blood biochemistry markers were
reported to be useful for risk stratiﬁcation [8–17], and correspond-
ing guidelines have been published [3]. However, to our
knowledge, there are only three such reports from Asia, including
Japan [18–20]. Furthermore, each of these reports described small-
scale studies of 50–100 cases and either demonstrated relation-
ships between BNP and NT-ProBNP levels with right-sided heart
failure [18,19], or between longer CCU stays and hospitalization
times with elevated troponin levels [20], but did not directly
demonstrate relationships between these factors and in-hospital
prognosis. The present study is larger, with 441 cases, and is the
ﬁrst to demonstrate that blood biomarkers are prognostic factors
of acute-phase, 30-day mortality in Asian patients with acute
pulmonary embolism.
During acute pulmonary embolism, BNP secretion is thought to
occur in response to an increase in right-sided heart strain
consequent to sudden pulmonary hypertension, which is primarily
due to occlusion of the pulmonary artery. In the present study, the
BNP levels increased along with pulmonary embolism severity
and, relative to the surviving group, the BNP levels of the 30-day
mortality group were signiﬁcantly higher. Additionally, 30-day
mortality in cases with BNP levels <90 pg/mL was 0, indicating a
negative predictive value of 100%. Previous reports have found that
BNP and NT-ProBNP levels increased in acute pulmonary embolism
cases in which echocardiography and CT showed right ventricle
overload [18,19], noting that these levels could be used as
prognostic factors of the acute-phase prognosis [8–10]. Echocar-
diograms are the primary choice for diagnosis of right ventricular
dysfunction; however, echocardiograms require technical knowl-
edge, exhibit operator variability, and lack a clear standard for
determining the loss of right ventricular function. Because BNP
tests are widely used and easily performed, this prognostic factor
might be useful as a surrogate marker of loss of right ventricular
function.
Myocardial troponin increases at the time of myocardial
damage and provides a potent myocardium-speciﬁc marker. In
addition to ischemic heart disease, troponin increases are also
observed with tachycardia, sudden heart failure, pericarditis,
Takotsubo myocardiopathy, renal failure, sepsis, stroke, intense
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[14,15]. In the present study, 28.4% of patients were positive for
cardiac troponin, in agreement with Western reports of 32–43%
positive rates [16,17]. Additionally, the 30-day mortality rate
among troponin-positive cases was 10.3%, approximately 5-fold
the rate for troponin-negative cases. The qualitative troponin test
for 30-day mortality had a sensitivity, speciﬁcity, positive
predictive value, and negative predictive value of 66.7%, 73.3%,
10.3%, and 97.9%, respectively, providing a higher positive
predictive value than that of BNP. To date, reports have evaluated
the relationship between troponin levels, echocardiogram, and
electrocardiogram right-sided heart strain ﬁndings [17,19], as well
as the possible use of troponin as a prognostic factor for in-hospital
adverse events [12,13,20], acute-phase prognosis [16,17], and
long-term prognosis [16]. Unfortunately, the present study only
made qualitative evaluations and was unable to make quantitative
evaluations; nonetheless, in-hospital deaths and adverse events
are reportedly more common in cases with higher troponin levels
among all troponin-positive cases [17].
In the present study, it was found that severe cases, such as
massive and collapse cases, are not always troponin-positive.
These negative results may have occurred for the following
reasons. First, there is a window of time between onset of
pulmonary embolism and when the serum level of troponin
increases to detectable limits [21,22]. In the cases in which blood
tests were performed within 90 min of embolism onset, serum
troponin levels were all negative, regardless of the severity of
pulmonary embolism in the present study. Mu¨ller-Bardorff et al.
studied nine consecutive patients with moderate to severe acute
pulmonary embolism and onset of symptoms 3–6 h before
admission. They reported that troponin-T was negative in four
at admission, became positive in all within 8 h, peaked at a median
of 10 h, and was detectable for a median of only 40 h after clinical
presentation, contrary to patterns seen in acute myocardial
infarction [21]. Punukollu et al. also reported in 57 normotensive
patients with acute pulmonary embolisms that troponin might
peak and not be detected if >72 h have passed since the onset of
the normotensive pulmonary embolism [22]. Second, the cases in
the collapse and massive groups had extremely poor circulatory
dynamics, and therefore troponin produced in the myocardium
would not have circulated throughout the body. Thus, it is possible
that even severe cases will be troponin-negative if blood tests are
conducted during the initial examination; initially negative cases
might require re-evaluation after 12–24 h, depending on the case.
The present study demonstrated that blood glucose levels at
admission increased with pulmonary embolism severity. Further-
more, 30-day mortality increased with blood glucose levels.
Interestingly, hyperglycemia has been reported as a prognostic
factor for unfavorable short-term prognosis in patients admitted to
the intensive care unit for pulmonary embolism [23] as well as for
other diseases, including myocardial infarction, arrhythmia,
unstable angina, heart failure, stroke, gastrointestinal bleeding,
pneumonia, renal failure, and sepsis [24]. However, no conclusions
regarding whether strict control of blood glucose levels improves
prognoses for intensive care unit patients have been made [24].
In the present study, the D-dimer positivity rate of 95.6% was
exceptionally high. According to previous reports [2,3], the
negative predictive value of D-dimer status for diagnosing venous
thromboembolism is extremely high; in other words, a D-dimer-
negative case has a low likelihood of developing acute pulmonary
embolism. Here, however, D-dimer status was not a good indicator
of pulmonary embolism prognosis. Unfortunately, quantitative
evaluation was not performed. Even if it had been, D-dimer levels
do not readily reﬂect pulmonary embolism prognosis because
D-dimer also indicates a systemic reaction to the dissolving
thrombus and of increases in deep vein thrombosis andinﬂammatory diseases. In fact, many studies (with the exception
of one) did not reveal a relationship between D-dimer levels and
pulmonary embolism prognosis and severity [25].
After combining previous ﬁndings with our results, we propose
that, once a diagnosis of acute pulmonary embolism has been
made, an immediate risk stratiﬁcation should be performed based
on blood biochemistry markers. First, circulatory dynamics should
be evaluated, and cases with shock vital signs or in which systolic
blood pressure is reduced by >40 mmHg should be considered
high-risk; for these, catheter-based treatment and surgical
thrombectomy should be considered alongside thrombolytic
treatment with anticoagulant therapy. In cases with stable
circulatory dynamics and when determining the presence of
right-sided heart strain using echocardiography or CT, blood
biomarkers should be evaluated. If no right heart strain is observed
or not evaluated, troponin-negative cases with BNP levels
<90 pg/mL and blood glucose levels <150 mg/dL should be
considered low-risk and administered standard anticoagulation
therapy alone; early discharge should be considered. Cases in
which right-sided heart strain is observed with positive blood
biochemistry markers should be considered intermediate risk and
followed carefully.
Limitations
Diagnostic and treatment method selection was entrusted to
individual physicians, which might have inﬂuenced the determi-
nations of acute pulmonary embolism severity and associated 30-
day mortality.
Conclusion
Troponin, BNP, and blood glucose levels should be used as
prognostic factors for acute pulmonary embolism in Japanese
clinical settings.
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Appendix
The followings are the members of the Tokyo CCU Network:
Mitsui Memorial Hospital, Nihon University Itabashi Hospital,
Juntendo University Hospital, Toho University, Ohashi Medical
Center, Saiseikai Central Hospital, Showa University Hospital,
Sakakibara Heart Institute, Kosei General Hospital, St. Luke’s
International Hospital, Tokyo Women’s Medical University Hospi-
tal, Nishiarai Heart Center Hospital, Teikyo University Hospital, The
Cardiovascular Institute, Toranomon Hospital, Toho University
Omori Medical Center, Surugadai Nihon University Hospital, Tokyo
Medical University Hachioji Medical Center, Kyorin University
Y. Tanabe et al. / Journal of Cardiology 66 (2015) 460–465 465Hospital, Tokyo Metropolitan Geriatric Hospital, Tokyo Metropoli-
tan Hiroo Hospital, Nippon Medical School Hospital, Tokyo
Women’s Medical University Medical Center East, Tokyo Metro-
politan Bokutoh Metropolitan General Hospital, Tobu Chiiki
Hospital, Musashino Red Cross Hospital, Showa General Hospital,
Tokyo Metropolitan Tama Medical Center, Disaster Medical Center,
Ome Municipal General Hospital, Edogawa Hospital, Tokyo Rinkai
Hospital, Jikei University Katsushika Medical Center, IMS Katsush-
ika Heart Center, Ayase Heart Hospital, Hakujikai Memorial
Hospital, The Jikei University Hospital, Senpo Tokyo Takanawa
Hospital, Kanto Medical Center NTT EC, Ikegami General Hospital,
The University of Tokyo Hospital, Tokyo Metropolitan Police
Hospital, Mishuku Hospital, Keio University Hospital, Tokyo
Medical University Hospital, National Center for Global Health
and Medicine, Kawakita General Hospital, Itabashi Chuo Medical
Center, Toshima Hospital, Nishitokyo Central General Hospital,
Higashiyamato Hospital, Tokai University Hachioji-hospital,
Nippon Medical School Tama-Nagayama Hospital, Tokyo Medical
and Dental University, Japanese Red Cross Medical Center, Kanto
Central Hospital, National Hospital Organization Tokyo Medical
Center, Social Insurance Central General Hospital, Tokyo Kosei
Nenkin Hospital, Jikei University Daisan Hospital, Tokyo-kita Social
Insurance Hospital, Kasai Shoikai Hospital, Tokyo Heart Center,
Ogikubo Hospital, Tama-Hokubu Medical Center, Meirikai Chuo
General Hospital, Juntendo University Nerima Hospital, and Fuchu
Keijinkai Hospital.
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